Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome

详细信息    查看全文

• 作者：Knut Michael Nowak¹ ; ^{knut.nowak@uk-essen.de} ; Oliver Witzke² ; ³ ; Georgios C. Sotiropoulos¹ ; Tamas Benkö ; ¹ ; Melanie Fiedler⁴ ; Jö ; rg Timm⁴ ; Andreas Kribben² ; Benjamin Wilde² ; Fuat Saner¹ ; Andreas Paul¹ ; Jü ; rgen Treckmann¹
• 关键词：HCV-negative recipients ; HCV-positive donors ; kidney transplantation ; safety
• 刊名：Kidney International Reports
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：2
• 期：1
• 页码：53-59
• 全文大小：865 K
• 卷排序：2

文摘

Because of the shortage of available organs for renal transplantation, strategies enabling the safe use of organs from donors with potential chronic infections such as hepatitis C are necessary. The aim of this study was to analyze the outcome of renal transplant donation from hepatitis C virus (HCV)-positive donors.MethodsBetween September 2002 and May 2007, 51 kidneys (34 donors) reactive for HCV antibodies were further evaluated. Six kidneys (5 donors) were transplanted to 6 recipients with known chronic HCV infection. The remaining 29 donors underwent extended virological testing. Nine donors were HCV RNA positive and thus not suitable for HCV-negative patients. Twenty donors (21 kidneys) did not have detectable HCV RNA copies and were transplanted into 21 HCV-negative recipients. Clinical outcomes focusing on safety, allograft function, and de novo HCV infection in the recipient were collected.ResultsThere were no de novo HCV infections detected in recipients who were HCV negative before transplantation. The extended virological donor screening did not have an impact on median cold ischemia time. Five-year graft survival was 75%.DiscussionOrgans from anti-HCV-reactive, nonviremic donors can be transplanted safely to HCV-negative recipients.